Phase II study in patients with primary TNBC randomized to T-FEC ( paclitaxel 80 mg/m ( 2 ) i.v. weekly for 12 weeks , followed by 5-fluorouracil 500 mg/m ( 2 ) , epirubicin 100 mg/m ( 2 ) , and cyclophosphamide 500 mg/m ( 2 ) every 3 weeks for four cycles ) versus TR-FEC ( paclitaxel 80 mg/m ( 2 ) i.v. and everolimus 30 mg PO weekly for 12 weeks , followed by FEC ) .